Nuwellis, Inc. (NUWE)
| Market Cap | 255.54K -95.3% |
| Revenue (ttm) | 8.77M -0.2% |
| Net Income | -19.04M |
| EPS | -563.49 |
| Shares Out | 84.06K |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 119,285 |
| Open | 2.907 |
| Previous Close | 2.880 |
| Day's Range | 2.870 - 3.200 |
| 52-Week Range | 2.750 - 908.251 |
| Beta | 0.30 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 13, 2026 |
About NUWE
Nuwellis, Inc., a medical device company, develops, manufactures, and commercializes medical devices used in ultrafiltration therapy. The company provides Aquadex FlexFlow and Aquadex SmartFlow systems, which are used to treat patients suffering from fluid overload due to heart failure, as well as Aquadex SmartFlow system for temporary use in adult and pediatric patients. The company was formerly known as CHF Solutions, Inc. and changed its name to Nuwellis, Inc. in April 2021. Nuwellis, Inc. was founded in 1999 and is headquartered in Eden Pra... [Read more]
Financial Performance
In 2025, Nuwellis's revenue was $8.27 million, a decrease of -5.38% compared to the previous year's $8.74 million. Losses were -$17.52 million, 64.9% more than in 2024.
Financial StatementsNews
Nuwellis to Showcase Aquadex Therapy at KidneyBee Summit 2026
MINNEAPOLIS, July 07, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, announces its par...
Nuwellis Proxy statement: Proxy filing
Nuwellis filed a proxy statement on July 7, 2026, providing details for shareholder voting and corporate governance matters.
Nuwellis Celebrates Five Years of Support of the Pediatric Cardiac Critical Care Consortium (PC⁴)
MINNEAPOLIS, June 26, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, announces the fiv...
Nuwellis Proxy statement: Proxy filing
Nuwellis filed a proxy statement on June 26, 2026, providing details for shareholder voting and corporate governance matters.
Nuwellis Inc trading halted, news pending
19:50 EDT Nuwellis (NUWE) Inc trading halted, news pending
Nuwellis Announces Pediatric Expansion in Michigan with First Aquadex SmartFlow® Installations
MINNEAPOLIS, June 25, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, announces its exp...
Incoming Nuwellis CEO Mike McCormick Underscores Strategic Priorities for Continued Market Expansion in Pediatric Category and Revenue Generation in Letter to Shareholders
MINNEAPOLIS, June 24, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, reviews the year-...
Nuwellis highlights clinical utility of its Aquadex SmartFlow system
Nuwellis (NUWE) highlighted the clinical utility of its Aquadex SmartFlow system at the 4th annual Critical Care Cardiology Education Summit, hosted by the University of Minnesota. As part of the…
Nuwellis Expands Critical Care Education with Aquadex Training at University of Minnesota Critical Care Cardiology Education Summit
MINNEAPOLIS, June 18, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, highlighted the c...
Nuwellis CEO transition to transition out of role, Mike McCormick to succeed
Nuwellis (NUWE) announced the appointment of Mike McCormick as CEO, effective June 30. John Erb, who currently serves as president, CEO, and chairman of the board, will transition from his…
Nuwellis Appoints Mike McCormick as Chief Executive Officer
Transition to become effective June 30, 2026; current CEO John Erb to continue as Chairman of the Board Transition to become effective June 30, 2026; current CEO John Erb to continue as Chairman of th...
Nuwellis expands collaboration with South Carolina healthcare system
Nuwellis (NUWE) announced an expanded collaboration with a major South Carolina healthcare system to integrate Aquadex SmartFlow devices into the clinical care programs at one of its children’s hospit...
Nuwellis Expands Collaboration with Major South Carolina Healthcare System to Install New Aquadex SmartFlow® Devices at One of its Children's Hospitals
South Carolina healthcare provider also upgrades to latest Aquadex devices at its two locations that already use the technology South Carolina healthcare provider also upgrades to latest Aquadex devic...
Nuwellis Announces Closing of $6.0 Million Registered Public Offering
MINNEAPOLIS , June 08, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, today announces ...
Nuwellis 20M share secondary priced at 30c
Nuwellis (NUWE) announces the pricing of a public offering of 20M shares of its common stock with accompanying warrants to purchase common stock for gross proceeds of approximately $6M. The…
Nuwellis Announces Pricing of $6 Million Public Offering
MINNEAPOLIS, June 05, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, today announces t...
Nuwellis Registration statement: Registration filing
Nuwellis filed a registration statement on June 4, 2026, providing details about a securities offering with the SEC.
Nuwellis Slides: Investor presentation
Nuwellis has posted slides in relation to its latest quarterly earnings report, which was published on June 2, 2026.
Nuwellis Registration statement: Registration filing
Nuwellis filed a registration statement on May 29, 2026, providing details about a securities offering with the SEC.
Nuwellis files to sell 4.85M shares of common stock, warrants
Ladenburg Thalmann is acting as exclusive placement agent.
Nuwellis Registration statement: Registration filing
Nuwellis filed a registration statement on May 22, 2026, providing details about a securities offering with the SEC.
Nuwellis completes Aquadex SmartFlow System pre-submission meeting with the FDA
Nuwellis (NUWE) announced the completion of a recent pre-submission meeting with the FDA regarding the proposed label expansion of the Aquadex SmartFlow System to support pediatric patients weighing 5...
Nuwellis Announces Successful Completion of FDA Pre-Submission 510(k) Meeting to Expand Aquadex Label
Proposal would extend treatment access to pediatric patients weighing 5 kg and above Proposal would extend treatment access to pediatric patients weighing 5 kg and above
Nuwellis Earnings Call Transcript: Q1 2026
Q1 2026 saw 26% revenue growth, improved gross margin, and a strengthened leadership team. Pediatrics now accounts for half of U.S. revenue, and a strategic acquisition expands the product portfolio. Cash burn reduction and disciplined capital allocation remain priorities.
Nuwellis Earnings release: Q1 2026
Nuwellis released its Q1 2026 earnings on May 12, 2026, summarizing the period's financial results.